Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed glioblastoma * Measurable disease by MRI * Completed standard first-line treatment for glioblastoma including surgery (unless not received due to anatomical location), radiotherapy and temozolomide (last dose given at least 28 days prior to enrollment) * No other prior treatment for glioblastoma except Gliadel or steroids * Recurrent or progressive disease after standard first-line treatment * No disease progression within 3 months of completion of radiotherapy * No intra- or peri-tumoral hemorrhage PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * Mini-mental status score ≥ 15 * Life expectancy ≥ 12 weeks * Serum bilirubin, ALT/AST, creatinine, and urine protein normal * Adequate bone marrow reserve * Not pregnant or nursing * Normal ECG * No history of familial long QT syndrome * No absorption or swallowing difficulties * No uncontrolled hypertension or cardiac ventricular arrhythmias * No current or history of uncontrolled hypertension or requiring maximal doses of calcium channel blockers * No severe or uncontrolled disease * No history of lung disease * No recent hemorrhage or hemoptysis * No known hypersensitivity to cediranib maleate, gefitinib, or any excipients * No history of other malignancies except adequately treated basal cell or squamous cell carcinoma or carcinoma in situ within the past 5 years, unless disease-free for 2 years with tissue diagnosis * No known HIV positivity * No known hepatitis B or C infection * No unhealed surgical incision * Not involved in planning or conducting this study PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from prior anticancer therapy, including radiotherapy * At least 3 months since prior cranial radiation * At least 30 days since prior investigational drugs * At least 28 days since prior craniotomy * At least 2 weeks since prior enzyme-inducing antiepileptic drugs * At least 2 weeks since prior and no concurrent dexamethasone (\> 8 mg/day) or equivalent * At least 14 days since prior major surgery or brain biopsy * No concurrent steroids OR on stable dose 5 days prior to baseline MRI * No other concurrent anticancer therapy, except for steroids (dexamethasone only) * No previous enrollment on the current study * No prior inhibitors of angiogenesis, EGFR, or downstream targets * No prior radiosurgery or brachytherapy